81.78

3.05% -2.57

After Hours: 81.85 0.07 +0.09%

Ionis Pharmaceuticals Inc (IONS)

Overview News Price History Option Chain Financials Discussions Forecast

Ionis Pharmaceuticals Inc stock is traded at $81.78, with a volume of 1.70M. It is down -3.05% in the last 24 hours and up +0.15% over the past month. Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Previous Close:

$84.35

Open:

$84.2

24h Volume:

1.70M

Relative Volume:

0.71

Market Cap:

$13.25B

Revenue:

$705.14M

Net Income/Loss:

$-453.90M

P/E Ratio:

-26.90

EPS:

-3.04

Net Cash Flow:

$-551.29M

1W Performance:

-2.04%

1M Performance:

+0.15%

6M Performance:

+97.49%

1Y Performance:

+165.18%

1-Day Range:

$81.20

$84.91

1-Week Range:

$81.20

$86.59

52-Week Range:

$23.95

$86.74

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name

Ionis Pharmaceuticals Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(760) 931-9200

Address

2855 GAZELLE COURT, CARLSBAD, CA

Employee

927

Twitter

@ionispharma

Next Earnings Date

2024-11-06

Latest SEC Filings

IONS's Discussions on Twitter

Compare IONS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IONS Ionis Pharmaceuticals Inc	81.78	13.66B	705.14M	-453.90M	-551.29M	-3.04
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Resumed	Barclays	Overweight
Oct-08-25	Upgrade	JP Morgan	Neutral → Overweight
Sep-26-25	Upgrade	Goldman	Sell → Neutral
Sep-03-25	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jul-31-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-01-25	Upgrade	Barclays	Equal Weight → Overweight
Apr-07-25	Initiated	H.C. Wainwright	Buy
Mar-31-25	Initiated	Redburn Atlantic	Neutral
Aug-02-24	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jul-24-24	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-16-24	Resumed	Jefferies	Buy
Jun-14-24	Upgrade	Bernstein	Underperform → Mkt Perform
Apr-10-24	Upgrade	Wolfe Research	Peer Perform → Outperform
Jan-02-24	Upgrade	BofA Securities	Neutral → Buy
Oct-23-23	Upgrade	BofA Securities	Underperform → Neutral
Sep-29-23	Initiated	Raymond James	Strong Buy
Jul-31-23	Upgrade	Citigroup	Neutral → Buy
Jun-07-23	Resumed	Piper Sandler	Overweight
May-04-23	Upgrade	Citigroup	Sell → Neutral
Mar-21-23	Initiated	Bernstein	Underperform
Dec-21-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-09-22	Resumed	Morgan Stanley	Overweight
Jul-18-22	Resumed	Oppenheimer	Outperform
Mar-31-22	Resumed	Piper Sandler	Overweight
Mar-01-22	Initiated	Citigroup	Sell
Mar-01-22	Initiated	Guggenheim	Buy
Feb-01-22	Downgrade	BofA Securities	Buy → Underperform
Dec-14-21	Upgrade	William Blair	Mkt Perform → Outperform
May-07-21	Upgrade	UBS	Sell → Neutral
Mar-01-21	Upgrade	Barclays	Underweight → Equal Weight
Dec-16-20	Initiated	UBS	Sell
Dec-15-20	Upgrade	Cowen	Market Perform → Outperform
Sep-14-20	Resumed	JP Morgan	Neutral
Sep-02-20	Initiated	The Benchmark Company	Hold
Jun-01-20	Resumed	Oppenheimer	Outperform
May-13-20	Initiated	RBC Capital Mkts	Outperform
Mar-05-20	Initiated	Citigroup	Buy
Dec-13-19	Initiated	Oppenheimer	Outperform
Nov-13-19	Initiated	BofA/Merrill	Buy
Nov-07-19	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Sep-10-19	Upgrade	Bernstein	Mkt Perform → Outperform
Aug-08-18	Reiterated	Stifel	Hold
Aug-07-18	Reiterated	Stifel	Hold
May-08-18	Downgrade	Evercore ISI	Outperform → In-line
Oct-06-17	Resumed	Goldman	Sell
Aug-17-17	Initiated	Evercore ISI	Outperform
Aug-09-17	Reiterated	Stifel	Hold
Mar-10-17	Downgrade	Goldman	Neutral → Sell
Dec-28-16	Reiterated	BMO Capital Markets	Outperform
Dec-27-16	Reiterated	Leerink Partners	Mkt Perform

View All

Ionis Pharmaceuticals Inc Stock (IONS) Latest News

01:51 AM

Severe Hypertriglyceridemia Market: High-Growth Opportunities for Investors to 2034DelveInsight - openPR.com

01:51 AM

05:45 AM

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

05:45 AM

Feb 11, 2026

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Yahoo Finance

Feb 11, 2026

Ionis to hold fourth quarter and full year 2025 financial results webcast - Caledonian Record

Feb 11, 2026

Ionis Pharmaceuticals (IONS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat

Feb 11, 2026

Ionis Pharma CEO Monia sells $2.52m in shares By Investing.com - Investing.com Canada

Feb 11, 2026

Ionis Pharma CEO Monia sells $2.52m in shares - Investing.com

Feb 11, 2026

Feb 10, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia Sells 29,430 Shares - MarketBeat

Feb 10, 2026

Feb 09, 2026

Ionis Pharmaceuticals (IONS) Valuation Check As Dawnzera Approval And Other Milestones Support Growth Prospects - Sahm

Feb 09, 2026

Candriam S.C.A. Has $39.99 Million Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Feb 09, 2026

Feb 07, 2026

Stock Recap: Why is Ionis Pharmaceuticals Inc stock going upWeekly Market Report & Consistent Income Trade Ideas - baoquankhu1.vn

Feb 07, 2026

Wealth Enhancement Advisory Services LLC Sells 15,476 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Feb 07, 2026

Feb 06, 2026

Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 6 Analysts - Benzinga

Feb 06, 2026

Ionis Pharmaceuticals (IONS) Sees Price Target Raised by Piper S - GuruFocus

Feb 06, 2026

More Rivalry With Ionis In A Potentially ‘Transformational’ Year For Arrowhead - Citeline News & Insights

Feb 06, 2026

Ionis Pharmaceuticals stock hits 52-week high at 86.31 USD By Investing.com - Investing.com South Africa

Feb 06, 2026

Feb 05, 2026

Ionis Regulatory Wins Highlight Growing Rare Disease Revenue Potential - Sahm

Feb 05, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 1-Year HighWhat's Next? - MarketBeat

Feb 05, 2026

Ionis Pharmaceuticals stock hits 52-week high at 86.31 USD - Investing.com

Feb 05, 2026

Dawnzera Approval And Pipeline Wins Could Be A Game Changer For Ionis Pharmaceuticals (IONS) - Yahoo Finance

Feb 05, 2026

C WorldWide Group Holding A S Sells 24,000 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Feb 05, 2026

Feb 04, 2026

Insider Sell: C Bennett Sells 85,089 Shares of Ionis Pharmaceuti - GuruFocus

Feb 04, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $7,056,430.77 in Stock - MarketBeat

Feb 04, 2026

New York State Common Retirement Fund Sells 8,026,750 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Feb 04, 2026

Feb 03, 2026

Understanding the Setup: (IONS) and Scalable Risk - Stock Traders Daily

Feb 03, 2026